{
    "clinical_study": {
        "@rank": "48452", 
        "arm_group": {
            "arm_group_label": "Somatropin", 
            "description": "Children with growth hormone deficiency treated with somatropin as Zomacton\u00ae according to the marketing authorization"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the long-term treatment with Zomacton\u00ae for\n      pituitary short stature in children with insufficient growth hormone production and/or short\n      stature caused by Turner's syndrome."
        }, 
        "brief_title": "Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton\u00ae", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Growth Hormone Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  therapeutic need according to the approved specific products characteristics (SPC)\n\n        Exclusion Criteria:\n\n          -  contraindication according to the SPC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Children with inadequate secretion of growth-hormone; growth retardation due to Turner's\n        syndrome"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731028", 
            "org_study_id": "000091"
        }, 
        "intervention": {
            "arm_group_label": "Somatropin", 
            "description": "Somatropin powder and solvent for solution for injection", 
            "intervention_name": "Somatropin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2013", 
        "number_of_groups": "1", 
        "official_title": "Non-interventional, Observational Study of the Application of Zomacton\u00ae in the Treatment of Growth Hormone Deficiency in Routine Clinical Practice", 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Efficacy of Zomacton\u00ae treatment measured by the increase in body height per annuum", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy of Zomacton\u00ae treatment measured by the increase in body weight per annuum", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Safety of Zomacton\u00ae and the application device measured by local adverse reactions to the application device", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013", 
        "why_stopped": "Change of local requirements"
    }
}